** Shares of drugmaker Axsome Therapeutics AXSM.O rise 5.9% to $108.98 premarket
** Company reports Q2 revenue of $150 mln, higher than analysts' estimate of $138.8 mln, according to data compiled by LSEG
** Says sales of its depression drug Auvelity were $119.6 mln in Q2, up 84% from $65 mln a year ago
** Reports Q2 net loss per share of 97 cents, less than loss of $1.67 per share a year earlier
** Up to last close, stock up 21.8% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.